Organisation paid for research Program year 2025 Source: CMS Open Payments

Optimus U

Neither a doctor nor a teaching hospital

Research payments

$27,876,954

56 payments

Through program year 2025, Optimus U is reported as receiving $27,876,954 in research payments, across 56 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$2,466,481	6
2024	Research	$8,610,127	14
2023	Research	$7,990,238	12
2022	Research	$5,286,070	8
2021	Research	$3,307,818	4
2020	Research	$686	1
2019	Research	$215,534	11

Breakdown

Who paid Research payments · program years 2019–2025

Eli Lilly and Company $24,366,137 29 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $3,116,393 10 payments
Avanir Pharmaceuticals, Inc. $216,220 12 payments
Avid Radiopharmaceuticals, Inc. $89,596 1 payment
Alnylam Pharmaceuticals Inc. $88,008 3 payments
AbbVie, Inc. $600 1 payment

Studies the money was for Research payments · program years 2019–2025

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $8,641,808 8 payments
Assessment of Safety, Tolerability, and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer's Disease $8,140,250 5 payments
Assessment of Safety Tolerability and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer's Disease $4,481,914 2 payments
A Study of Donanemab (Ly3002813) in Participants With Early Alzheimer's Disease (Trailblazer-Alz 2) $1,517,010 1 payment
POCC in NASH $1,142,164 2 payments
PoCP study Phase Ib of NR2B modulation in MDD $880,439 2 payments
Obesity Long term safety in patients with CV risk $769,200 1 payment
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease $739,977 3 payments
Assessment of Safety, Tolerability, and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer's Disease $542,521 1 payment
A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-Avwa in Participants With Early Symptomatic Alzheimer's Disease $221,860 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.